U.S. Bioscience last week highlighted the potential downside to striking marketing deals with emerging pharmaceutical companies when it ended a 1996 U.S. co-promotion agreement with Alza Corp. for two of three UBS products. UBS said it terminated the deal because its partner's increasing product portfolio would not allow